ITN Opens the EXTEND Study in Type 1 Diabetes
A new ITN type 1 diabetes trial opened today at the first site, Sanford Health in Sioux Falls, SD.
Latest News
Request for Proposals: ITN Seeks Antigen-Specific T Cell Tolerance Assays for Myelin-Associated Antigens in Multiple Sclerosis
The ITN has an interest in antigen-specific T cell tolerance in multiple sclerosis, an autoimmune disease in which autoreactive T cells specific for myelin-associated antigens are thought to play a role in pathogenesis. Assessment of antigen-specific tolerance in multiple sclerosis will require reliable assays to detect and phenotype T cell responses to myelin-associated antigens in a clinical trial setting. To this end, the ITN is seeking assays for assessing functional tolerance and biomarkers of tolerance in antigen-specific CD4 and CD8 effector and regulatory T cells.
Immunotherapy Research in Seattle and the ITN
An article in Seattle Magazine about the landscape for immunotherapy in Seattle gives a nice mention of the Benaroya Research Institute and the Immune Tolerance Network:
Stem Cell Transplants May Halt Progression of Multiple Sclerosis
Washington, DC - Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, a progressive autoimmune disease in which the immune system attacks the brain and spinal cord.
CALIBRATE Trial for Lupus Nephritis Opens
Last Friday the Immune Tolerance Network (ITN) opened a new combination therapy study in lupus nephritis, CALIBRATE, at University of California, San Francisco (UCSF). The CALIBRATE Study will be led by Drs. Betty Diamond (North Shore Feinstein Institute), David Wofsy (UCSF), Cynthia Aranow (North Shore Feinstein Institute), and Maria Dall’Era (UCSF), and will test a novel regimen of rituximab (Rituxan, Genentech, Inc.) followed by belimumab (BENLYSTA®, GlaxoSmithKline) in patients with refractory lupus nephritis.
Abatacept for Lupus Nephritis (the ACCESS Study)
The results of the ACCESS study, “Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis” sponsored by the Immune Tolerance Network (ITN) and led by Drs.
ITN Launches the CATNIP Cat Allergy Immunotherapy Study
On Wednesday, October 8th the ITN opened the CATNIP study, “Anti-TSLP plus antigen-specific immunotherapy for induction of tolerance in individuals with cat allergy,” at the first site, the University of Wisconsin. CATNIP will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP antibody being co-developed by Amgen and Medimmune) can lead to lasting tolerance to cat allergen.
New White Paper - Tolerance: One Transplant for Life
A White Paper published yesterday in Transplantation (co-authored by ITN Deputy Director Larry Turka, MD) outlines recommendations from an international workshop convened by The Transplantation Society (TTS) to determine the necessary steps to make tolerance protocols a standard of care for transplant over the next decade. To date three academic centers have employed successful tolerance-inducing protocols in kidney transplant recipients (Stanf
Immune Tolerance Network’s (ITN) TrialShare Wins National Academies Board on Research Data and Information Challenge
The Immune Tolerance Network’s (ITN) TrialShare Clinical Trials Research Portal (www.ITNTrialShare.org) has won the National Academy of Sciences Data and Information Challenge. The theme of this year’s competition, launched and judged by the academy’s Board on Research Data and Information (BDRI), was “Using Data for the Public Good.”